Condition (MeSH)
IgG Deficiency
ClinicalTrials.gov lists 8 trials for IgG Deficiency or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with IgG Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did IgG Deficiency trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2013 | 2 |
| 2007 | 1 |
| 2005 | 1 |
| 2004 | 3 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are IgG Deficiency trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 1 |
How many IgG Deficiency trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 7 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most IgG Deficiency trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CSL Behring | 3 |
| Prothya Biosolutions | 1 |
Which serious adverse events do IgG Deficiency trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Aggression | 1 | 1 |
| Angioedema | 1 | 1 |
| Cellulitis | 1 | 1 |
| Clostridial infection | 1 | 1 |
| Gastrointestinal hemorrhage | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover IgG Deficiency? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD. | Respiratory research | 2022 | Yes |
| Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. | Respiratory research | 2018 | Yes |
| The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13. | Vaccine | 2017 | Yes |
| Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. | Journal of clinical immunology | 2012 | Yes |
| [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]. | Medizinische Klinik (Munich, Germany : 1983) | 2010 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.